BUDGETARY IMPACT OF TREATMENT GUIDELINES—THE EXAMPLE OF TYPE 2 DIABETES
Author(s)
Pirk O1, Goertz A2, Spannheimer A3, Reitberger U3, Liebl A4, 1Fricke & Pirk, Nuremberg, Germany; 2GlaxoSmithKline, Munich, Germany; 3Kendle International Inc, Munich, Germany; 4Diabetes Stoffwechselzentrum Tegernsee, Rottach-Egern, Germany
OBJECTIVES: Treatment costs for type 2 diabetic patients in Germany amount to more than 31 billion DM per year, mainly because of related complications. In accordance with the St. Vincent declaration, these complications should be reduced at least by a third by treating according to current guidelines. METHODS: The CODE-2 study results described the actual treatment of diabetic patients and associated costs. This analysis focuses on those 47% of diabetic patients who had no complications, with the aim of preventing long-term complications in these patients. The European Diabetes Policy Group guidelines were applied to define the optimal therapy regarding blood glucose, lipids and blood pressure. Costs of guideline-related medication (antidiabetic, lipid lowering agents and antihypertensive drugs) and costs of additional outpatient treatment were calculated using official tariffs. These results were compared to the cost of current treatment as assessed in CODE-2. RESULTS: Guideline treatment would induce 1,270 DM cost per patient for additional medication and outpatient treatment. For office-based physicians who treat nearly 10% of their patients for diabetes, that would mean a budget increase of nearly 90000 DM per year for each physician. Thus, for all of Germany annually about 2.1 billion DM would have to be invested in diabetes patients who do not have complications. CONCLUSIONS: Treatment of patients with type 2 diabetes according to the guidelines makes a huge investment necessary. Nevertheless, this could be balanced by avoiding long-term complications in the future. Assuming that optimal treatment according to guidelines could prevent one third of diabetes-related complications and by using the published data of the CODE-2 study, potential cost savings of 2.9 billion DM could be achieved by avoiding late complications of diabetes, which actually exceeds the cost of prevention.
Conference/Value in Health Info
2001-11, ISPOR Europe 2001, Cannes, France
Value in Health, Vol. 4, No. 6 (November/December 2001)
Code
PDG16
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Diabetes/Endocrine/Metabolic Disorders